Back to Search
Start Over
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
- Source :
- Business Wire. March 10, 2020
- Publication Year :
- 2020
-
Abstract
- CAMBRIDGE, Mass. & OSAKA, Japan -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO[TM] (ixazomib) to lenalidomide [...]
- Subjects :
- Takeda Pharmaceutical Company Ltd. -- Product development
Ixazomib
Lithium compounds -- Product development
Multiple myeloma
Pharmaceutical industry -- Product development
Dexamethasone -- Product development
Lenalidomide
Glucocorticoids
Prescription writing
Business
Business, international
Ninlaro (Medication)
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.616905856